IP Library Granted Patent US 7,968,586
Granted Patent B2
US 7,968,586 · App. 12/090,453 · Granted Jun 28, 2011

Cytotoxic compounds and conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,586
App. No.
12/090,453
Granted
Jun 28, 2011
Kind
B2
Abstract

The present disclosure provides cytoxic compounds useful as drugs or prodrugs and to drug-cleavable substrate conjugates where the drug and cleavable substrate are optionally linked through a self-immolative linker.

Claims (29)

1. A compound of the formula

wherein X and Z are independently selected from O, S and NR 23 wherein R 23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;

R 1 is H, substituted or unsubstituted lower alkyl, C(O)R 8 , or CO 2 R 8 ,

R 1′ is H, substituted or unsubstituted lower alkyl, or C(O)R 8 , each R 8 is a member independently selected from NR 9 R 10 and OR 9 and R 9 and R 10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

R 2 is H, substituted or unsubstituted lower alkyl, unsubstituted heteroalkyl, cyano, or alkoxy;

R 2′ is H, substituted or unsubstituted lower alkyl, or unsubstituted heteroalkyl,

R 3 is a member selected from the group consisting of SR 11 , NHR 11 and OR 11 , wherein R 11 is a member selected from the group consisting of H, substituted alkyl, unsubstituted alkyl, substituted heteroalkyl, unsubstituted heteroalkyl, diphosphates, triphosphates, acyl, C(O)R 12 R 13 , C(O)OR 12 , C(O)NR 12 R 13 , P(O)(OR 12 ) 2 , C(O)CHR 12 R 13 , SR 12 and SiR 12 R 13 R 14 , in which R 12 , R 13 , and R 14 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, or R 12 and R 13 together with the nitrogen or carbon atom to which they are attached are joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members;

R 6 is a single bond which is either present or absent and when present R 6 and R 7 are joined to form a cyclopropyl ring; and

R 7 is CH 2 —X or —CH 2 — joined in said cyclopropyl ring with R 6 , wherein X 1 is a leaving group,

R 4 , R 4 ′, R 5 and R 5 ′ are members independently selected from the group consisting of H, substituted alkyl, unsubstituted alkyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted heterocycloalkyl, unsubstituted heterocycloalkyl, halogen, NO 2 , NR 15 R 16 , NC(O)R 15 , OC(O)NR 15 R 16 , OC(O)OR 15 , C(O)R 15 , SR 15 , OR 15 , CR 15 ═NR 16 , and O(CH 2 ) n NR 24 R 25 wherein n is an integer from 1 to 20;

R 15 and R 16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, and substituted or unsubstituted peptidyl, wherein R 15 and R 16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms; and R 24 and R 25 are independently selected from hydrogen and unsubstituted alkyl, wherein at least one of R 24 and R 25 is hydrogen, and wherein at least one of R 4 , R 4 ′, R 5 and R 5 ′ is O(CH 2 ) n NR 24 R 25 .

2. The compound of claim 1 , wherein R 4 is O(CH 2 ) n NR 24 R 25 .

3. The compound of claim 2 , wherein R 4 is O(CH 2 ) n NH 2 .

4. The compound of claim 3 , wherein R 4 ′, R 5 and R 5 ′ are H.

5. The compound of claim 1 , wherein R 6 is absent and R 7 is CH 2 —X 1 , wherein X 1 is F, Cl, or Br.

6. The compound of claim 1 , wherein R 1 , R 1 ′, R 2 , and R 2 ′ are H.

7. The compound of claim 1 , wherein X is O and Z is O.

8. The compound of claim 1 , wherein the compound has the following formula:

9. The compound of claim 1 , wherein the compound has the following formula:

wherein X 1 is F, Cl, or Br.

10. The compound of claim 1 , wherein the compound has the following formula:

11. The compound of claim 1 , wherein the compound has the following formula:

12. The compound of claim 1 , wherein R 2 is CN.

13. The compound of claim 1 , wherein R 2 is methyl.

14. The compound of claim 1 , wherein X is O.

15. The compound of claim 1 , wherein Z is O.

16. The compound of claim 1 , wherein R 24 and R 25 are hydrogen.

17. A pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

18. The compound of claim 1 , having the formula:

Assignments (2)
MERGER Recorded Mar 19, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035226/0690 →
MERGER Recorded Jun 13, 2013
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 030603/0924 →